{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:45:43Z","timestamp":1770464743229,"version":"3.49.0"},"reference-count":0,"publisher":"Mattioli1885","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Pract Concept"],"abstract":"<jats:p>Introduction: Many topical drugs are used in the treatment of erythematotelangiectatic rosacea (ETR). However, dapsone 5% gel has never been used in ETR to date.\nObjectives: To evaluate the efficacy of dapsone 5% gel as a new treatment option for ETR.\nMethods: Thirty-five patients with ETR were included in the study. Diagnosis was made with National Rosacea Society criteria. Dapsone 5% gel was used topically twice a day for 12 weeks. Investigator Global Assessment (IGA) 4-point scale ( 0 \u2192 Clean, 1 \u2192 mild, 2 \u2192 moderate, 3 \u2192 severe, 4 \u2192 very severe), Visual Analogue Scale (VAS) and Dermatology Life Quality Index (DLQI) were used for evaluation (at baseline, 2nd, 6th, and 12th weeks).\nResults: IGA scores among baseline (2 \u2192 62.9%, 3 \u2192 34.3%, 4 \u2192 2.9%) and 2nd (1 \u2192 14.3%, 2 \u2192 77,1%, 3 \u2192 8.6%), 6th (1 \u2192 45,7%, 2 \u2192 54.3%) and 12th weeks (1 \u2192 62.9%, 2 \u2192 37.1%) were found to be statistically significant (P &lt; 0.001). Median VAS scores among baseline (median = 7 [5-9]) and 2nd (median=5 [3-8]), 6th (median=5 [3-6]) and 12th weeks (median = 4 [2-6]) were statistically significant (P &lt; 0.001). Median DLQI scores among baseline (median = 8 [6-14]) and 2nd (median = 5 [3-11]), 6th (median = 5 [3-11]) and 12th weeks (median = 4 [2-9]) were statistically significant (p&lt;0.001). Concurrent systemic disease was a risk factor for poor treatment response (P = 0.034). Mild irritation was observed in 3 patients (8.5%) during treatment.\nConclusions: Dapsone 5% gel was effective and well tolerated in ETR treatment.<\/jats:p>","DOI":"10.5826\/dpc.1401a34","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T18:00:26Z","timestamp":1706724026000},"page":"e2024034","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Topical Dapsone 5% Gel for the Treatment of Erythematotelangiectatic Rosacea: New Treatment Option with Old Drug"],"prefix":"10.5826","author":[{"given":"\u015eule","family":"G\u00f6k\u015fin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u015f\u0131l","family":"G\u00f6\u011fem \u0130mren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nida","family":"Ka\u00e7ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27750","published-online":{"date-parts":[[2024,1,31]]},"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/3629\/2430","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/3629\/2430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T18:00:27Z","timestamp":1706724027000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/3629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":0,"URL":"https:\/\/doi.org\/10.5826\/dpc.1401a34","relation":{},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}